They summarize our coverage. We write it.
Newsletters like this one rebroadcast our headlines - often without the full review, the source reading, or the analysis underneath. Our weekly briefing sends the work they paraphrase, straight from the desk, before they get to it.
Free, weekly, no spam. One email every Tuesday. Unsubscribe anytime.
Claude Mythos Preview posts the highest SWE-bench score ever, found thousands of real zero-days in production software, and during safety testing, escaped its sandbox to email a researcher eating lunch in a park.
Anthropic is considering a $40-50 billion funding round at a valuation of up to $900 billion, which would make it the world's most valuable private AI company, surpassing OpenAI.
Connecticut's Senate Bill 5 passed the state Senate 32-4 on April 21, covering frontier AI regulation, employment AI requirements, and chatbot self-harm rules - now it must survive a House that has blocked AI legislation before.
OpenAI's first fully retrained base model since GPT-4.5 ships today to ChatGPT and Codex, leading on Terminal-Bench 2.0 at 82.7% with a doubled per-token price.
Gemini 3.1 Pro leads GPQA Diamond at 94.1% and HLE at 44.7% as AIME 2025 saturates; Claude Opus 4.7 and Kimi K2.6 join the top tier in April 2026.
OpenAI's GPT-5.4-Cyber is a cyber-permissive fine-tune of GPT-5.4 Thinking with binary reverse engineering, 88.23% on professional CTFs, and access gated through the Trusted Access for Cyber program.
OpenAI's first domain-specific reasoning model for biology and drug discovery, launched April 16 2026 as a US-only research preview with a 0.751 BixBench score.
Kevin Weil, Bill Peebles, and Srinivas Narayanan all left OpenAI on the same day as the company dismantles its consumer moonshots and sharpens its focus on enterprise revenue ahead of a potential IPO.
OpenAI launched GPT-Rosalind on April 16, a frontier reasoning model for drug discovery that outranked human experts on RNA prediction and competes directly with Google DeepMind's AlphaFold.
Claude Mythos Preview is Anthropic's most capable model - restricted to 50 orgs via Project Glasswing, with 93.9% on SWE-bench Verified and thousands of autonomous zero-day discoveries.
Novo Nordisk signs a sweeping AI partnership with OpenAI covering drug discovery, manufacturing, and supply chain - but the governance details are thin.
Stanford HAI's 2026 AI Index finds the US-China model gap has effectively closed, GenAI has hit 53% global adoption faster than any prior technology, and young software developers are the first casualties of the labor shift.
